98%
921
2 minutes
20
Background: Oral immunotherapy (OIT) is a promising therapeutic approach to treat food allergic patients. However, concerns with regards to safety and long-term efficacy of OIT remain. There is a need to identify biomarkers that predict, monitor and/or evaluate the effects of OIT. Here we present a method to select candidate biomarkers for efficacy and safety assessment of OIT using the computational approaches Bayesian networks (BN) and Topological Data Analysis (TDA).
Results: Data were used from fructo-oligosaccharide diet-supported OIT experiments performed in 3 independent cow's milk allergy (CMA) and 2 independent peanut allergy (PNA) experiments in mice. Bioinformatical approaches were used to understand the data structure. The BN predicted the efficacy of OIT in the CMA with 86% and indicated a clear effect of scFOS/lcFOS on allergy parameters. For the PNA model, this BN (trained on CMA data) predicted an efficacy of OIT with 76% accuracy and shows similar effects of the allergen, treatment and diet as compared to the CMA model. The TDA identified clusters of biomarkers closely linked to biologically relevant clinical symptoms and also unrelated and redundant parameters within the network.
Conclusions: Here we provide a promising application of computational approaches to a) compare mechanistic features of two different food allergies during OIT b) determine the biological relevance of candidate biomarkers c) generate new hypotheses to explain why CMA has a different disease pattern than PNA and d) select relevant biomarkers for future studies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480866 | PMC |
http://dx.doi.org/10.1186/s12859-019-2802-9 | DOI Listing |
J Allergy Clin Immunol Glob
November 2025
Allergy Center, National Center for Child Health and Development, Tokyo, Japan.
Background: Adverse events could be a barrier to implementing oral immunotherapy (OIT) in children with hen's egg (HE) allergy, highlighting the need for safer OIT methods.
Objective: To determine the safety and efficacy of a new OIT method in a single-center, phase II, double-blind, parallel-group, randomized controlled trial.
Methods: Children aged 1 to 18 years with HE allergy whose cumulative tolerated dose (CTD) range was greater than or equal to 0.
Int J Hematol
August 2025
Department of Medical Oncology (Division of pediatric hematology oncology), KAHER'S Jawaharlal Nehru Medical College, Belagavi, Karnataka, India.
Background: Iron deficiency anemia (IDA) is the leading cause of nutritional anemia. In some cases, oral iron therapy (OIT) fails to achieve an optimal therapeutic response. Oral doses of iron acutely increase serum hepcidin, resulting in decreased iron absorption and poor response treatment.
View Article and Find Full Text PDFClin Exp Allergy
August 2025
Department of Allergy and Immunology, The Children's Hospital at Westmead, Westmead, New South Wales, Australia.
Background: Sustained unresponsiveness (SU) remains a major challenge for peanut OIT. The short chain fatty acid (SCFA) butyrate has the potential to upregulate regulatory T cells (Tregs) to improve long term tolerance. We conducted a superiority randomised controlled trial to assess the efficacy and safety of the addition of daily oral butyrate to peanut OIT.
View Article and Find Full Text PDFJ Food Allergy
August 2024
From the Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina and.
Background: Peanut allergy remains a common problem that persists into adulthood for most patients, with risks of accidental ingestion and poor quality of life. Oral immunotherapy (OIT) and anti-immunoglobulin E (IgE) therapy are effective options for peanut allergy; however, each therapy has limitations, which makes them not ideal for all patients.
Objective: The objective was to summarize recent studies that support sublingual immunotherapy (SLIT) for peanut allergy as an alternative option to OIT and anti-IgE therapy, and to discuss practical considerations for its use in clinical practice.
Omalizumab is approved for the management of immunoglobulin E-mediated food allergy in individuals ages ≥ 1 year. Approval for food allergy followed the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (OUtMATCH) study, which demonstrated that omalizumab increases the threshold dose of multiple food allergens needed to elicit an allergic reaction. Despite the demonstrated efficacy in food allergy and favorable safety profile, many questions remain.
View Article and Find Full Text PDF